-
公开(公告)号：EP3838290A1
公开(公告)日：2021-06-23
申请号：EP20212555.5
申请日：2017-06-22
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université de la Réunion Saint Denis , Institut De Recherche Pour Le Développement (IRD) , Centre National de la Recherche Scientifique (CNRS)
IPC分类号： A61K39/12
摘要： The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.
-
公开(公告)号：EP3481848A1
公开(公告)日：2019-05-15
申请号：EP17739939.1
申请日：2017-07-07
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université de la Réunion Saint Denis , Institut de Recherche pour le Développement (IRD) , Centre National de la Recherche Scientifique (CNRS)
IPC分类号： C07K14/005 , C12N7/04 , C12N15/113
-
公开(公告)号：EP3474891A1
公开(公告)日：2019-05-01
申请号：EP17733424.0
申请日：2017-06-22
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université de la Réunion Saint Denis , Institut de Recherche pour le Développement (IRD) , Centre National de la Recherche Scientifique (CNRS)
IPC分类号： A61K39/12
-
4.发明授权DENGUE AND WEST NILE VIRUS PROTEINS AND GENES AND THEIR THERAPEUTIC APPLICATION 有权蛋白及基因来自新登革热和西尼罗河病毒和治疗用途
公开(公告)号：EP1599495B9
公开(公告)日：2013-11-13
申请号：EP04714865.5
申请日：2004-02-26
CPC分类号： A61K39/12 , A61K38/00 , A61K39/00 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C07K14/1825 , C12N15/86 , C12N2760/18443 , C12N2770/24122 , C12Q1/701 , Y02A50/386 , Y02A50/394 , Y02A50/53
摘要： The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre- m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.
-
5.发明授权DENGUE AND WEST NILE VIRUS PROTEINS AND GENES AND THEIR THERAPEUTIC APPLICATION 有权蛋白及基因来自新登革热和西尼罗河病毒和治疗用途
公开(公告)号：EP1599495B1
公开(公告)日：2012-08-29
申请号：EP04714865.5
申请日：2004-02-26
CPC分类号： A61K39/12 , A61K38/00 , A61K39/00 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C07K14/1825 , C12N15/86 , C12N2760/18443 , C12N2770/24122 , C12Q1/701 , Y02A50/386 , Y02A50/394 , Y02A50/53
摘要： The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre- m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.
-
6.发明公开
公开(公告)号：EP1599495A2
公开(公告)日：2005-11-30
申请号：EP04714865.5
申请日：2004-02-26
IPC分类号： C07K14/18
CPC分类号： A61K39/12 , A61K38/00 , A61K39/00 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C07K14/1825 , C12N15/86 , C12N2760/18443 , C12N2770/24122 , C12Q1/701 , Y02A50/386 , Y02A50/394 , Y02A50/53
摘要： The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre- m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.
-
7.发明公开RECOMBINANT MEASLES VIRUS EXPRESSING CHIKUNGUNYA VIRUS POLYPEPTIDES AND THEIR APPLICATIONS 有权CHIKUNGUNYA-VIRUS-POLYPEPTIDE ZUR EXPRESSION EINES REKOMBINANTEN MASERNVIRUS UND ANWENDUNGEN DAVON
公开(公告)号：EP2900687A1
公开(公告)日：2015-08-05
申请号：EP13771106.5
申请日：2013-09-26
申请人： INSTITUT PASTEUR , Themis Bioscience GmbH , Centre National de la Recherche Scientifique (CNRS)
CPC分类号： A61K39/12 , A61K38/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/5258 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2760/18421 , C12N2760/18434 , C12N2760/18443 , C12N2760/18444 , C12N2770/36122 , C12N2770/36123 , C12N2770/36134 , Y02A50/383
摘要： The invention relates to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus.
摘要翻译： 本发明涉及表达基孔肯雅病毒多肽的重组麻疹病毒，特别涉及其表面上含有基孔肯雅病毒的包膜和衣壳蛋白的病毒样颗粒（VLP）。 这些颗粒是能够在给药后在宿主中复制的重组感染性颗粒。 本发明提供了用于产生这些重组感染性颗粒的方法，特别是核酸，载体，细胞和营养系统。 本发明还涉及这些重组感染性颗粒，特别是组合物形式，特别是在疫苗制剂中用于治疗或预防基孔肯雅病毒感染的用途。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.028 秒)
